I can only provide my opinion based on my pharma experience on why this is taking so log... Leronlimab is moving thru phase 2 and phase 3 trials faster than any drug i was associated with. . Hell the drug was EIND in the last quarter when the FDA said "stop and go do your clinical trials so we can get this thing reviewed quickly". EIND doesnt get you on the approval road but it is supporting evidence. So both S/C and M/M are moving incredibly fast in drug approval terms. Leronlimab"s strike is its catagorized as an experimental drug because its never been approved by the FDA for any application whereas, as marginally useful Remdisivir, it was an approved drug and a known entity to the FDA